Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
RLY-2608 的发现和临床概念验证，这是一种一流的突变选择性变构 PI3Kα 抑制剂，可将抗肿瘤活性与高胰岛素血症分离开来
期刊:Cancer Discovery
影响因子:29.7
doi:10.1158/2159-8290.CD-23-0944
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio #, Artemisa Bulku #, Lucian DiPietro, Cary Fridrich, Adam Frost, Fabrizio Giordanetto, Erika P Hamilton, Katherine Harris, Michael Holliday, Tamieka L Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jo
